MGMA joining Denver innovation hub

Beth Walsh | | Health Exec | Precision Medicine

The Medical Group Management Association (MGMA) will be one of the tenants of a new healthcare technology hub in Denver.

The Catalyst Health-Tech Innovation development will include other health-focused organizations, practice groups, health finance companies and high-tech organizations.

MGMA, which represents more than 33,000 medical practice leaders, is headquartered in Englewood, Colo., and the 5,000-square-foot addition to its existing campus will be part of the Catalyst Health-Tech Innovation development.

The additional space will provide an environment for MGMA staff and leaders to collaborate with other industry leaders on developing efficient and cost-effective strategies for medical practices and improving care for patients, said MGMA President and CEO Halee Fischer-Wright, MD, in a statement.

The hub is scheduled to open in 2018.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup